dalpiciclib
3 clinical trials
3 products
16 abstracts
1 indication
1 target
Indication
Breast CancerTarget
CDK4Abstract
Neoadjuvant dalpiciclib, exemestane, and goserelin in premenopausal women with HR-positive, HER2-negative breast cancer: A prospective, multicenter, randomized two-group, non-controlled phase 2 clinical trial.Org: Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Hemay Pharmaceutical, China National Biotec Group, Tianjian,
Abstract
A phase II trial comparing dalpiciclib in combination with letrozole versus standard chemotherapy as neoadjuvant therapy in patients with high-risk HR- positive HER-2 negative breast cancer: DARLING-02.Org: The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, Affiliated Hospital of Hebei Engineering University, Handan, China, First Hospital of Qinhuangdao, Qinhuangdao, China, Qinhuangdao Maternal and Child Health Hospital, Qinhuangdao, China,
Abstract
Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study.Org: Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China, Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, Breast Surgery, Jiangxi Cancer Hospital, Nanchang, China, Hunan Cancer Hospital, Changsha, China, Breast Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, China,
Abstract
Efficacy and safety of neoadjuvant trastuzumab, pyrotinib, and dalpiciclib without chemotherapy in early-stage HR-negative/HER2-positive breast cancer: An open-label, single-arm phase II trial.Org: The First People's Hospital of Xiangtan City, Xiangtan, ShaoYang Central Hospital,
Abstract
A phase 2 trial of the CDK4 inhibitor dalpiciclib in well-differentiated or dedifferentiated liposarcoma.Org: Rare Tumors Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Huaiyin District Jinan, China, Rare Tumors Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, Rare Tumors Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, China, Department of Medicine, Qingdao University, Qingdao, China,
Abstract
Dalpiciclib and chidamide in patients with HR+/HER2- advanced breast cancer and resistance to CDK4/6 inhibitors: A phase Ib trial.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China,
Abstract
Efficacy and safety of dalpiciclib, fulvestrant, and pyrotinib in HR+ HER2-low advanced breast cancer following cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors and aromatase inhibitors (AIs): A Bayesian optimal phase II trial.Org: First Hospital of China Medical University,
Abstract
Neoadjuvant dalpiciclib combined with aromatase inhibitors in stage I-III HER2 negative luminal B breast cancer (DANCER): Preliminary findings from an ongoing phase II study.Org: Genecast Precision Medical Diagnostic Laboratory, Wuxi Co., Ltd, Wuxi, China,
Clinical trial
Efficacy and Safety of Dalpiciclib in HR+/HER2- Advanced Breast Cancer: a Real-world StudyStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Abstract
Neoadjuvant adebrelimab plus dalpiciclib in HPV-negative locally advanced head and neck squamous cell carcinoma: A phase II clinical trial.Org: National Clinical Research Center for Oral Diseases, Department of Head and Neck Oncology Surgery,
Clinical trial
Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer:a Single-arm, Phase II Exploratory Clinical StudyStatus: Recruiting, Estimated PCD: 2025-11-30
Clinical trial
Efficacy and Safety of Mecapegfilgrastim for Prophylaxis of Dalpiciclib -Induced Neutropenia in Patients With Advanced HR+/HER2- Breast Cancer: a Open-label, Multicenter, Investigator-initiated, Randomized Controlled Phase II TrialStatus: Recruiting, Estimated PCD: 2023-12-01
Abstract
Updated results from a phase 2 study on dalpiciclib and pyrotinib, a dual-oral chemotherapy-free regimen in HER2-positive advanced breast cancer (DAP-HER-01).Org: Department of Breast Disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
A prospective, phase II, neoadjuvant clinical study based on chemotherapy sensitivity in hormone receptor–positive, HER2-negative breast cancer: FINEST study.Org: Fudan University Shanghai Cancer Center, Shanghai Cancer Center, Shanghai, China, Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University, Shangai, China, Jiangsu Hengrui Pharmaceuticals Co., Ltd.,
Abstract
PLEASURABLE: Results and biomarkers analysis from the phase II study of dalpiciclib combined with pyrotinib and endocrine therapy (ET) in women with dual-receptor positive (ER+/HER2+) metastatic breast cancer (MBC).Org: Fudan University Shanghai Cancer Center, Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, China, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Department of Breast Oncology, Peking University Cancer Hospital, Harbin Medical University Cancer Hospital,
Abstract
Neoadjuvant stereotactic body radiotherapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer.Org: Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China,
Abstract
Neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for triple-positive breast cancer: A pilot trial.Org: Jiangsu Hengrui Pharmaceuticals Co.,Ltd,
Abstract
Preliminary analysis of pyrotinib and dalpiciclib-based therapy in HER2-positive advanced breast cancer (ABC).Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong University of Traditional Chinese Medicine Affiliated Hospital, Jinan, China, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Science,Peking Union Medical College, Chinese Academy of Medical Sciences and Peking Union Medical College,
Product
dalpiciclib + cetuximab